A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer

Roche

Description

This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women with locally advanced breast cancer and HER2/c-erbB-2 gene amplification. In a parallel observational study patients with HER2-negative disease will receive the same chemotherapy without Herceptin.

Citations (0)

No citations found

It looks like this dataset has no citations.

Mentions (0)

No mentions found

It looks like this dataset has not been mentioned in any sources.

Metrics

Dataset Index

0.3

FAIR Score

31%

Citations

Mentions

Metrics Over Time

Publication Details

DOI

10.25934/pr00008284

Publisher

Vivli

License

Study data may be accessed by completing a request form at https://vivli.org. It will then be reviewed according to the data contributor’s governance policy, see https://vivli.org/members/ourmembers/ for Vivli member’s review process. If approved, use of the data is governed by the data use agreement at https://vivli.org/resources/vivli-data-use-agreement/

Assigned Domain

Subfield

Cancer Research

Field

Biochemistry, Genetics and Molecular Biology

Domain

Life Sciences

Confidence Score

56%

Source

Scholar Data Model

Keywords

Conditions: Breast CancerInterventions: TrastuzumabInterventions: DoxorubicinInterventions: PaclitaxelInterventions: CMF

Normalization Factors

40.38

CTw

1.00

MTw

1.00